Testing a New Cancer Treatment Called IM-1617
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic or locally advanced) cancer that cannot be cured with surgery, including colorectal, lung, breast, esophageal, or gastric cancer
- Your cancer has progressed after, or you could not tolerate, standard treatments available for your specific cancer type
- Your cancer can be measured on imaging scans (RECIST criteria)
- You are able to perform daily activities with minimal assistance (ECOG performance status 0, 1, or 2)
- You have not been treated with certain similar drugs called antibody-drug conjugates with topoisomerase inhibitors (with limited exceptions for lung or breast cancer)
- You do not have active brain tumors, meningeal involvement, or a life expectancy under 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.